Subtype
Breast Carcinoma by Gene Expression Profile
CI-CAN-00004666Explore in graph →
537 active trials6 approved drugs101 evidence items
- NCIt
- C53553
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004666Explore in graph →
Clinical trials
1,299 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (217)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06646263 | Cellular Immune Responses in Triple-negative Breast Cancer - High Throughput Immunogenetic Studies | enrolling by invitation | — | 150 | Institute of Applied BiosciencesOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 |
| NCT04547907 | A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer | recruiting | Phase 3 | 688 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 20, 2024 | clinicaltrials |
| NCT05019690 | Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 29 | Fujian Cancer HospitalOTHER_GOV | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06586866 | JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases | not yet recruiting | Phase 2 | 25 | JenKem Technology Co., Ltd.INDUSTRY | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06548178 | T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer | not yet recruiting | Phase 2 | 242 | Fudan UniversityOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT05710666 | Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study) | active not recruiting | Phase 2 | 11 | Cancer Trials IrelandNETWORK | 1 | Aug 5, 2024 | clinicaltrials |
| NCT06497322 | Exercise Intervention in Women Diagnosed With Triple-negative Breast Cancer Receiving Oncologic Treatment | not yet recruiting | N/A | 60 | University Hospital of CologneOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT05635487 | A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients | recruiting | Phase 2 | 65 | Shengjing HospitalOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT04790305 | Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer | recruiting | Phase 4 | 1,072 | Fudan UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06313086 | DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer | recruiting | Phase 3 | 442 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | May 10, 2024 | clinicaltrials |
| NCT06407310 | Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer | not yet recruiting | Phase 2 | 25 | Tel Aviv Medical CenterOTHER | 0 | May 9, 2024 | clinicaltrials |
| NCT06404736 | QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer(QUEEN-Dream) | not yet recruiting | Phase 2 | 73 | Fudan UniversityOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06385990 | Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy | recruiting | Phase 2 | 53 | Hunan Cancer HospitalOTHER | 1 | Apr 26, 2024 | clinicaltrials |
| NCT06371807 | Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab(KEYPARTNER) | not yet recruiting | Phase 2 | 20 | Fundacao ChampalimaudOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT03281954 | Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo | active not recruiting | Phase 3 | 1,550 | NSABP Foundation IncNETWORK | 2 | Apr 8, 2024 | clinicaltrials |
| NCT06330012 | The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients. | recruiting | N/A | 50 | Samsung Medical CenterOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT05433753 | Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study | recruiting | — | 60 | National Cancer Center, JapanOTHER_GOV | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06217185 | The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). | recruiting | Phase 4 | 100 | Hebei Medical University Fourth HospitalOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06281210 | Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery(BETTY-CRASY) | recruiting | N/A | 77 | European Institute of OncologyOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06259162 | LAG3 Expression in Triple Negative Breast Cancer | recruiting | N/A | 128 | Samsung Medical CenterOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT04282044 | Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 60 | BioEclipse TherapeuticsINDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05760378 | Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. | recruiting | Phase 3 | 223 | Fudan UniversityOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06229067 | Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer | not yet recruiting | Phase 2 | 182 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jan 29, 2024 | clinicaltrials |
| NCT05746897 | A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 38 | Hefei TG ImmunoPharma Co., Ltd.OTHER | 1 | Jan 26, 2024 | clinicaltrials |
| NCT02641847 | TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature | active not recruiting | Phase 2 / Phase 3 | 503 | Fudan UniversityOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT06202313 | Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer | not yet recruiting | Phase 2 | 128 | Shengjing HospitalOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT05451784 | Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS(TILS001) | recruiting | Phase 1 / Phase 2 | 20 | Fundacio Clinic BarcelonaOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT06035016 | Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer | recruiting | — | 300 | Peking Union Medical College HospitalOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT05955521 | Exosome as the Prognostic and Predictive Biomarker in EBC Patients | active not recruiting | N/A | 200 | Samsung Medical CenterOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT05916755 | Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform(PORTRAIT) | recruiting | — | 100 | Vall d'Hebron Institute of OncologyOTHER | 1 | Jun 23, 2023 | clinicaltrials |
| NCT05843292 | Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer(NeoSTEP) | not yet recruiting | Phase 4 | 48 | Shanghai Jiao Tong University School of MedicineOTHER | 0 | Jun 6, 2023 | clinicaltrials |
| NCT05447702 | Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | recruiting | Phase 2 | 35 | West China HospitalOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT05834764 | Pyrotinib in Women With High-risk in Early Stage Breast Cancer | recruiting | Phase 2 | 188 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT02315196 | Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer | active not recruiting | Phase 2 | 62 | Rutgers, The State University of New JerseyOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT04501523 | A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC(Apollo) | recruiting | Phase 2 | 460 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05698186 | Thero2-01S22 in HER2-positive Breast Cancer | not yet recruiting | Phase 3 | 320 | Institut de cancérologie Strasbourg EuropeOTHER | 0 | Jan 26, 2023 | clinicaltrials |
| NCT05627960 | First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies | recruiting | Phase 1 | 77 | A&G Pharmaceutical Inc.INDUSTRY | 1 | Nov 28, 2022 | clinicaltrials |
| NCT05388500 | Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)(PHARE-C) | not yet recruiting | Phase 3 | 800 | Institut de cancérologie Strasbourg EuropeOTHER | 0 | May 27, 2022 | clinicaltrials |
| NCT05037825 | The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors(PARADIGM) | recruiting | — | 800 | VastBiomeINDUSTRY | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05067530 | Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study(CAREGIVER) | not yet recruiting | Phase 2 | 126 | Medical University of GdanskOTHER | 1 | Oct 5, 2021 | clinicaltrials |
| NCT04993014 | Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer(HER2Cell) | recruiting | Phase 2 | 80 | AC Camargo Cancer CenterOTHER | 1 | Aug 6, 2021 | clinicaltrials |
| NCT04481763 | A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast | recruiting | Phase 1 / Phase 2 | 20 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Jul 22, 2020 | clinicaltrials |
| NCT04481932 | Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer | recruiting | Phase 2 | 104 | Peking UniversityOTHER | 1 | Jul 22, 2020 | clinicaltrials |
| NCT04437160 | Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy | recruiting | Phase 2 | 286 | Chinese Academy of Medical SciencesOTHER | 1 | Jun 18, 2020 | clinicaltrials |
| NCT04281641 | Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer(PHC-BC) | recruiting | N/A | 94 | Fudan UniversityOTHER | 1 | May 4, 2020 | clinicaltrials |
| NCT04301739 | to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC) | not yet recruiting | Phase 3 | 522 | Shanghai Henlius BiotechINDUSTRY | 0 | Mar 12, 2020 | clinicaltrials |
| NCT04225858 | Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy(ASICS) | not yet recruiting | N/A | 340 | The Netherlands Cancer InstituteOTHER | 0 | Jan 13, 2020 | clinicaltrials |
| NCT04158856 | Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer(SHERO) | not yet recruiting | Phase 2 | 60 | xuexin heOTHER | 0 | Nov 12, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Oct 17, 2024source: clinicaltrials